Apellis advances late-stage studies of pegcetacoplan in vision loss disorder

Apellis Pharmaceuticals (NASDAQ:APLS) has completed enrollment in two Phase 3 clinical trials, DERBY and OAKS, evaluating Fast Track-tagged pegcetacoplan (APL-2) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, an eye disorder that can lead to blindness.

The primary endpoint of both studies is the reduction in GA lesion size from baseline at month 12.

The estimated primary completion date for DERBY is March 2021 and a month later for OAKS.

https://seekingalpha.com/news/3589012-apellis-advances-late-stage-studies-of-pegcetacoplan-in-vision-loss-disorder